MarketCapExport financials
Eiger BioPharmaceuticals (EIGR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Eiger BioPharmaceuticals Cash Flow 2023-2011 | EIGR
Brief overview of Eiger BioPharmaceuticals's cash generation
Cash flow changes are traced through the five latest available reports from 2019 to 2023.
Operating cash flow is negative at -$74.5 million, leaving internal funding capacity weak.
Only 0 of five observations were above zero. The business relies heavily on individual strong periods.
What the cash flows show
Eiger BioPharmaceuticals's cash profile looks stretched: weak operating cash flow limits investment, payouts and debt-servicing capacity.
Annual Cash Flow Eiger BioPharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-74.5 M | -83 M | -71.3 M | -63.2 M | -63.6 M | -42.7 M | -38.4 M | -38 M | - | - | - | - | - |
Depreciation & Amortization |
275 K | 292 K | 276 K | 167 K | 68 K | 54 K | 41 K | 23 K | 11 K | 8 K | 7.23 K | 64 K | - |
Accounts Payables |
2.12 M | 8.98 M | 7.76 M | 4.64 M | 6.41 M | 5.83 M | 3.18 M | 2.64 M | 1.94 M | 59.3 K | 1.4 M | - | - |
Accounts Receivables |
1.68 M | 1.75 M | 2.58 M | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
1.56 M | 2.85 M | 2.61 M | 93 K | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow Eiger BioPharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-60.6 M | -46 M | -24 M | - | -60.8 M | -40.2 M | -18.5 M | - | -54.6 M | -35.3 M | -14.9 M | - | -47.7 M | -33.6 M | -17.7 M | - | -48.6 M | -34.1 M | -18.9 M | - | -30.2 M | -16.5 M | -8.57 M | - | -28 M | -19.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
218 K | 140 K | 74 K | - | 219 K | 146 K | 73 K | - | 203 K | 135 K | 67 K | - | 112 K | 72 K | 36 K | - | 41 K | 27 K | 13 K | - | 34 K | 22 K | 11 K | - | 30 K | 19 K | 9 K | - | 15 K | 9 K | 4 K | - | 371 K | 153 K | 76 K | - | 110 K | 60 K | 26 K | - | 49 K | 33 K | 17 K | - | - | - | - | - | - | - | - |
Accounts Payables |
4.86 M | 4.95 M | 11.9 M | 8.98 M | 10.5 M | 9.94 M | 9.22 M | 7.76 M | 6.75 M | 4.44 M | 7.75 M | 4.64 M | 8.25 M | 5.18 M | 8.87 M | 6.41 M | 9.06 M | 7.19 M | 5.52 M | 5.83 M | 6.52 M | 4.44 M | 3.02 M | 3.18 M | 4.17 M | 4.47 M | 3.19 M | 2.64 M | 4.08 M | 1.25 M | 6.06 M | 1.94 M | 228 K | 2.76 M | 2.79 M | 59.3 K | 2.2 M | 1.09 M | 731 K | 1.4 M | 1.4 M | 1.4 M | 1.4 M | - | - | - | - | - | - | - | - |
Accounts Receivables |
1.32 M | 3.72 M | 3.89 M | 1.75 M | 2.46 M | 1.04 M | 2.29 M | 2.58 M | 2.76 M | 1.44 M | 639 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
1.1 M | 1.1 M | 5.34 M | 2.85 M | 2.82 M | 2.88 M | 1.91 M | 2.61 M | 2.62 M | 2.06 M | 1.4 M | 93 K | 93 K | 93 K | 93 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Eiger BioPharmaceuticals, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Vaxcyte
PCVX
|
$ 60.43 | -3.85 % | $ 8.22 B |  USA |
 |
INmune Bio
INMB
|
$ 1.46 | -5.19 % | $ 36.1 M | USA |
 |
Passage Bio
PASG
|
$ 3.37 | -3.99 % | $ 10.8 M | USA |
 |
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | USA |
 |
Keros Therapeutics
KROS
|
$ 11.28 | -0.62 % | $ 420 M | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.59 | -2.45 % | $ 156 M | USA |
|
Immatics N.V.
IMTX
|
$ 7.31 | -3.05 % | $ 894 M |  Germany |
 |
Immunic
IMUX
|
$ 7.41 | 2.63 % | $ 1.15 B | USA |
 |
Immunovant
IMVT
|
$ 28.41 | -2.37 % | $ 5.18 B | USA |
 |
Kura Oncology
KURA
|
$ 9.61 | -2.54 % | $ 843 M | USA |
 |
Iovance Biotherapeutics
IOVA
|
$ 14.09 | -0.35 % | $ 5.03 M | USA |
|
Rezolute
RZLT
|
$ 3.86 | -0.13 % | $ 401 M | USA |
 |
Eli Lilly and Company
LLY
|
$ 1 273.46 | -2.49 % | $ 1.14 T | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M |  Canada |
 |
Krystal Biotech
KRYS
|
$ 311.5 | -2.7 % | $ 9.02 B | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
$ 434.24 | -4.21 % | $ 9.74 B | USA |
 |
Grifols, S.A.
GRFS
|
$ 7.56 | 1.48 % | $ 5.14 B |  Spain |
 |
MacroGenics
MGNX
|
$ 2.25 | -38.02 % | $ 142 M | USA |
 |
Milestone Pharmaceuticals
MIST
|
$ 0.65 | -7.76 % | $ 69.1 M | Canada |
 |
MannKind Corporation
MNKD
|
$ 3.19 | -0.31 % | $ 975 M | USA |
|
Monopar Therapeutics
MNPR
|
$ 70.65 | -2.66 % | $ 524 M | USA |
 |
Marker Therapeutics
MRKR
|
$ 0.96 | -10.27 % | $ 14.7 M | USA |
 |
Moderna
MRNA
|
$ 200.1 | -1.25 % | $ 77.8 B | USA |
|
Silence Therapeutics plc
SLN
|
$ 19.67 | 0.05 % | $ 2.79 B |  Britain |
 |
Minerva Neurosciences
NERV
|
$ 2.3 | -4.17 % | $ 19.5 M | USA |
 |
Aligos Therapeutics
ALGS
|
$ 4.78 | -1.24 % | $ 47.3 M | USA |
 |
Alkermes plc
ALKS
|
$ 43.63 | -1.24 % | $ 7.19 B |  Irlanda |
 |
Jazz Pharmaceuticals plc
JAZZ
|
$ 214.0 | -0.3 % | $ 13 B | Irlanda |
 |
Novavax
NVAX
|
$ 9.7 | -2.9 % | $ 1.57 B | USA |
 |
Novartis AG
NVS
|
$ 151.12 | -3.3 % | $ 293 B |  Schweiz |
 |
Kymera Therapeutics
KYMR
|
$ 110.76 | -0.08 % | $ 9.36 B | USA |
 |
Oramed Pharmaceuticals
ORMP
|
$ 4.13 | 0.24 % | $ 171 M |  Israel |
|
Larimar Therapeutics
LRMR
|
$ 2.35 | 3.52 % | $ 195 M | USA |
|
Phathom Pharmaceuticals
PHAT
|
$ 5.74 | -18.12 % | $ 419 M | USA |
 |
Praxis Precision Medicines
PRAX
|
$ 252.96 | -2.3 % | $ 5.69 B | USA |
 |
PainReform Ltd.
PRFX
|
$ 0.74 | 2.76 % | $ 480 K | Israel |
 |
Protagonist Therapeutics
PTGX
|
$ 138.43 | -0.79 % | $ 8.8 B | USA |
 |
Replimune Group
REPL
|
$ 11.46 | -4.42 % | $ 1.06 B | USA |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.11 | -4.31 % | $ 51.5 M | USA |
 |
REGENXBIO
RGNX
|
$ 6.68 | -6.83 % | $ 345 M | USA |
 |
Nanobiotix S.A.
NBTX
|
$ 29.36 | 0.58 % | $ 1.4 T |  France |
 |
Viking Therapeutics
VKTX
|
$ 24.4 | -5.54 % | $ 2.75 B | USA |
 |
Seer
SEER
|
$ 1.97 | 0.51 % | $ 109 M | USA |
 |
Intellia Therapeutics
NTLA
|
$ 11.21 | 0.45 % | $ 1.21 B | USA |
|
Nuvation Bio
NUVB
|
$ 4.57 | -2.45 % | $ 1.56 B | USA |
 |
Processa Pharmaceuticals
PCSA
|
$ 1.81 | -2.69 % | $ 2.37 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
$ 0.42 | 0.26 % | $ 5.18 B | Israel |
 |
Sol-Gel Technologies Ltd.
SLGL
|
$ 69.45 | 3.06 % | $ 193 M | Israel |
 |
SELLAS Life Sciences Group
SLS
|
$ 11.54 | 1.67 % | $ 1.26 B | USA |
 |
Syndax Pharmaceuticals
SNDX
|
$ 13.4 | -1.25 % | $ 1.16 B | USA |